Last week we joined the 2024 Congress of Neurological Surgeons (CNS) meeting in Houston where our partner ClearPoint Neuro, Inc. exhibited the ClearPoint Prism® Neuro Laser Therapy System, powered by CLS. In addition to good booth traffic and customer discussions, we also took part in the scientific program providing the latest updates on the use of Laser Interstitial Thermal Therapy (LITT) in neurosurgery.

Both abstracts provide the latest insights into the clinical use of focal laser ablation for prostate cancer, contributing to the ongoing development of minimally invasive cancer therapies.

On the 29th of August, CLS organized a training camp for our European distributors within urology and their Clinical Applications Specialists. During two intense days in Turin, Italy, the team learned a lot about the treatment of localized prostate cancer using the CLS TRANBERG® product portfolio, both in theory and in practice.

Now, when summer is approaching and we're all looking forward to enjoying some days off, it's time to sumarize the news from the first half of 2024.

The Imperial Prostate Masterclass meeting in London brings together key opinion leaders in urology and experts in focal therapy from around the world. AS part of the program CLS hosted a hands-on training session.

For CLS it has been an intense start to the year with many positive news. Read about what has been happening with a focus on actions to future proof our core technology, an update on market expansion, andew company presentations.